BRAIN Biotech AG Presents Preliminary Q2 Figures and Adjusted Future Outlook

BRAIN Biotech AG has released its preliminary Q2 financial figures for the fiscal year 2024/25, reporting EUR 12.12 million in revenues with an adjusted EBITDA of minus EUR 0.36 million. These figures were disclosed on April 30, 2025, in Zwingenberg, Germany. Despite this, the company anticipates a more conservative performance for the latter half of the fiscal year due to a challenging economic environment and significant USD currency fluctuations.

The company's revised forecast projects full-year revenues for its core BRAINBiocatalysts segment to remain consistent with last year's figures, falling short of the initial guidance. Meanwhile, guidance for the adjusted EBITDA margin in BRAINBiocatalysts and the BRAINBioIncubator segment remains unchanged. A comprehensive half-year report and analyst call are expected on May 28, 2025.